Common questions we get asked by clinicians, researchers, and mental health professionals regarding Abriella and its integration into healthcare.
A: Abriella is designed to complement existing NHS mental health services by providing AI-driven therapeutic support, streamlining low-level interventions, and freeing up clinicians to focus on complex cases. It is prescribed by GPs and mental health professionals.
A: No, Abriella is not intended to replace human therapists. It is designed to enhance clinician capacity by handling routine tasks such as mood tracking, journaling, and basic therapeutic interventions.
A: Abriella has been tested in controlled environments with promising results in improving patient engagement and reducing clinician workload. Future feasibility studies will validate its long-term efficacy in real-world NHS settings.
A: Abriella adheres to NHS Digital’s DCB0129 and DCB0160 standards for clinical risk management. We are aiming for certification as a Class 2A medical device, ensuring compliance with safety regulations.
A: Abriella provides structured 8-week CBT and MBCBT programs, once complete this can be further personalised based on patient data. The AI then adapts to individual progress, delivering evidence-based interventions that align with NHS treatment guidelines.
A: Yes, Abriella’s therapeutic programs can be tailored based on clinical assessments, with real-time adjustments made by healthcare professionals. The AI delivers personalised interventions and tracks progress.
A: Abriella uses encryption and adheres to strict NHS data security standards, ensuring patient data is protected and confidential. Access to data is limited to authorised healthcare professionals.
A: By automating routine tasks such as mood tracking, journaling, and delivering basic interventions, Abriella reduces clinician workload, enabling them to focus on high-priority cases and complex patients.
A: Abriella can assist in mental health triage by collecting initial patient data, tracking mood and symptoms, and delivering preliminary interventions while patients await clinical care, reducing waiting times.
A: Future plans include expanding Abriella’s capabilities for pain management, multi-language support, and integrating new therapeutic techniques based on ongoing clinical research and trials.